Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia
Trial details
- Registry ID
- NCT02612311
- Phase
- Phase 3
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic LeukemiaNCT02612311 | TGTX | Phase 3 | Terminated | 2023-02-22Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |